CD163 and non-small cell lung carcinoma: Moreover, Larroquette et al. performed ST on 16 NSCLC tumors using DSP to determine NSCLC cells with different expression levels of CD163+ and to explore the determining factors that affect the effect of immune checkpoint blockers in tumors with increasing CD163+ expression, and they found that tumors with high CD163+ cell infiltration showed upregulation of ITGAM, CD27, and CCL5 39.